For Invitrogen, Prodesse Pact Is Latest Feather In Dx Cap; Additional OEM Deals On the Way | GenomeWeb
Stepping up its efforts to push products into the burgeoning molecular diagnostics market, Invitrogen last week licensed its Lux reagent technology to Prodesse, a Wisconsin-based developer of multiplex PCR-based diagnostic tests.
 
The alliance is the latest in a series of actions taken by Invitrogen to further develop a variety of technologies acquired during its 2004-2005 buying spree for the molecular diagnostics field. The pact also furthers Invitrogen’s plans to greatly expand its OEM business.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.